California Life Sciences Association applauds confirmation of Dr. Scott Gottlieb as new FDA Commissioner
Will Zasadny (CLSA) | May 10, 2017 | California
SAN FRANCISCO & SAN DIEGO, CA – Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger
SACRAMENTO – Patients and the life sciences community have partnered to protect access to new medicines and oppose SB 1010. The bill, by Sen. Ed Hernandez, prioritizes paperwork and bureaucracy over research, and instead of improving patient access and affordability, places patients in California at the end of the line.
H.R. 5009 bridges Medicare patient access gaps and modernizes policies to allow coverage of technologies approved through FDA’s expedited review process Washington, DC (April 21, 2016) – California Life Sciences Association (CLSA), the statewide public policy organization representing over 750 of California’s leading life science innovators, lauded the introduction of
Sacramento, CA--California Life Sciences Association (CLSA), the statewide public policy organization representing over 750 of California’s leading life sciences innovators, issued the following statement opposing SB 1010. This statement can be attributed to Sara Radcliffe, President & CEO, California Life Sciences Association (CLSA): “As innovators in the life sciences sector
California Life Sciences Association (CLSA), the leading voice to drive innovation for California’s statewide life sciences sector, today released a new infographic report on the U.S. Food and Drug Administration’s (FDA) drug review and approval times over the last 15 years. Produced in partnership with The Boston Consulting Group, the